Biolinq Incorporated
Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company's biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous small molecule biosensing, aiming to bring biosensing and biowearables mainstream over the next decade.
Industries
Nr. of Employees
medium (51-250)
Patents
Method for improved sensor sensitivity of a microneedle-based continuous analyte monitoring system
US-12336816-B2
View Details
Method for improved sensor sensitivity of a microneedle-based continuous analyte monitoring system
US-12336816-B2
View DetailsProducts
Multi-analyte wearable intradermal biosensor patch
A wearable patch that houses an array of ultra-small electrochemical sensors placed just below the skin surface to continuously monitor glucose and other small-molecule analytes and provide real-time feedback.
Digital analytics and mobile health platform
Software and mobile applications that ingest continuous sensor data to produce analytics and contextualized metabolic health insights.
Multi-analyte wearable intradermal biosensor patch
A wearable patch that houses an array of ultra-small electrochemical sensors placed just below the skin surface to continuously monitor glucose and other small-molecule analytes and provide real-time feedback.
Digital analytics and mobile health platform
Software and mobile applications that ingest continuous sensor data to produce analytics and contextualized metabolic health insights.
Services
Design and execution of pivotal clinical trials in the US to generate clinical evidence in support of regulatory filings and commercialization readiness.
Design and implementation of manufacturing processes and operations for scalable production of microfabricated biosensors using semiconductor-based techniques.
Collaborative research and development with academic and bioengineering institutions to extend biomarker sensing capabilities and validate new applications on the platform.
Design and execution of pivotal clinical trials in the US to generate clinical evidence in support of regulatory filings and commercialization readiness.
Design and implementation of manufacturing processes and operations for scalable production of microfabricated biosensors using semiconductor-based techniques.
Collaborative research and development with academic and bioengineering institutions to extend biomarker sensing capabilities and validate new applications on the platform.
Expertise Areas
- Continuous glucose monitoring (CGM) and metabolic health monitoring
- Multi-analyte wearable biosensing
- Sensor microfabrication and semiconductor-scale production
- Electrochemical assay and sensor chemistry
Key Technologies
- Electrochemical microsensors
- Microneedle / intradermal sensing
- Microarray sensor platforms
- Silicon semiconductor fabrication for sensors
News & Updates
The Series C funding supports Biolinq’s transition from development stage to commercial readiness following US pivotal trial completion and regulatory submission.
Biolinq is developing a wearable patch that uses electrochemical sensors to measure glucose levels from just beneath the skin surface.
Biolinq aims to help people with Type 2 diabetes via a device that uses microneedles to measure blood sugar without requiring a secondary device.
Biolinq is planning to file for FDA clearance this year after starting a pivotal study in March 2024.
Biolinq has secured funding to advance biosensor technology for metabolic health, targeting clinical trials of a groundbreaking CGM device.
The wearable features a color-changing interface for quick glucose insights without a secondary device.
The Series C funding supports Biolinq’s transition from development stage to commercial readiness following US pivotal trial completion and regulatory submission.
Biolinq is developing a wearable patch that uses electrochemical sensors to measure glucose levels from just beneath the skin surface.
Biolinq aims to help people with Type 2 diabetes via a device that uses microneedles to measure blood sugar without requiring a secondary device.
Biolinq is planning to file for FDA clearance this year after starting a pivotal study in March 2024.
Biolinq has secured funding to advance biosensor technology for metabolic health, targeting clinical trials of a groundbreaking CGM device.
The wearable features a color-changing interface for quick glucose insights without a secondary device.